Monthly
Flexibility with month-to-month billing.
- Compounded DSIP therapy
- Licensed clinician oversight
- Care-team messaging
- Free discreet shipping
Delta Sleep-Inducing Peptide (DSIP) is explored for its potential role in promoting restful sleep and recovery. Truvera’s DSIP Sleep Optimization Therapy is designed for individuals seeking improved sleep quality and nighttime recovery through physician-guided care.
Potential Benefits
Short Version
A peptide therapy designed to support restorative sleep and recovery.
Peptide · Sleep Optimization
DSIP is a naturally occurring neuropeptide studied for its ability to promote slow-wave sleep and modulate the stress hormones that keep you wired at night. Prescribed by a licensed clinician, compounded to order, and shipped to your door.
How it works
From online intake to medication delivered — in as little as 3 days.
A 5-minute medical intake covers your health history, current sleep patterns, medications, and sleep optimization goals. No appointment needed.
A licensed US clinician reviews your intake and, if clinically appropriate, issues your DSIP prescription and compounding order.
Your DSIP is compounded at a licensed US pharmacy and shipped in discreet, temperature-controlled packaging.
Message your care team anytime. We monitor your response and adjust your protocol at every check-in.
Pricing
One monthly price covers your clinician visits, compounded medication, shipping, and care team access.
Flexibility with month-to-month billing.
Save 19% vs monthly
Best balance of savings and commitment.
Save 31% vs monthly
Our best price for long-term sleep optimization support.
DSIP is a compounded peptide, not an FDA-approved drug. Prescriptions are issued only at the discretion of licensed clinicians and only when medically appropriate.
Eligibility
What is DSIP?
Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring nonapeptide first isolated in 1974 by Swiss researchers Marcel Monnier and colleagues, who observed that perfusate from the thalamus of sleeping rabbits could induce slow-wave sleep in alert animals. The peptide was subsequently identified in human blood, cerebrospinal fluid, and various tissues, suggesting an endogenous role in sleep-wake regulation. Its primary mechanism centers on promoting delta wave electroencephalographic (EEG) activity during non-REM sleep — the deep, slow-wave stages most associated with physical restoration, memory consolidation, and growth hormone release.
Beyond direct sleep architecture effects, DSIP exhibits adaptogenic and stress-modulating properties through its actions on the hypothalamic-pituitary-adrenal (HPA) axis. Research has demonstrated that DSIP can suppress the release of ACTH (adrenocorticotropic hormone) and blunt the downstream cortisol response, offering a mechanistic explanation for its utility in stress-disrupted sleep. This neuroendocrine modulation distinguishes it from sedative-hypnotic agents: rather than simply inducing sedation, DSIP appears to work with the brain's existing sleep regulatory systems to restore normal slow-wave sleep architecture and dampen the hormonal activity that keeps the nervous system hypervigilant at night.
Human research on DSIP remains limited but intriguing. Early studies reported improvements in sleep quality scores and reductions in insomnia symptoms, with a favorable tolerability profile and no observed sedative hangover. DSIP has not completed the large-scale randomized trials required for FDA drug approval and is not approved as a pharmaceutical. It is available to patients through licensed compounding pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act, prescribed at the discretion of licensed clinicians based on individual clinical appropriateness.
Patient experience
"I've had poor sleep for years and tried everything — melatonin, magnesium, prescription sleep aids that left me groggy. Within three weeks on DSIP I was actually reaching deep sleep. I wake up feeling like I actually rested."
"My stress was clearly wrecking my sleep. I'd lie awake with my mind racing no matter how tired I was. After starting DSIP my clinician explained the cortisol connection and it makes total sense — I fall asleep faster and stay asleep."
"TruVera was honest that the research is still emerging, which I appreciated. My care team checked in regularly and the difference in how I feel during the day has been real. No grogginess, no dependency feeling — just better sleep."
FAQ
DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide first isolated in 1974, studied for its ability to promote slow-wave (delta) sleep and modulate HPA axis stress hormones including cortisol and ACTH. It is not FDA-approved as a standalone drug. TruVera provides DSIP through licensed compounding pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act — available only with a valid prescription from a licensed clinician.
Melatonin primarily regulates circadian timing — it signals when to sleep, not how deeply. Sedative-hypnotic sleep medications (benzodiazepines, z-drugs) work by broadly suppressing CNS activity, which can suppress deep slow-wave sleep, cause morning grogginess, and carry dependency risks. DSIP operates differently: it promotes delta wave EEG activity specifically during non-REM sleep and modulates HPA axis stress hormones, working with the brain's own sleep architecture rather than overriding it. It does not carry a sedative or dependency profile.
DSIP is typically administered via subcutaneous injection, usually shortly before bed. Your clinician will specify the dose, concentration, and injection protocol based on your intake and clinical profile. The care team will walk you through injection technique if needed, and your compounded medication will arrive with clear instructions.
Some patients report improvements in sleep depth and morning energy within 1–2 weeks; more consistent changes to sleep architecture are typically observed over 3–4 weeks of use. Individual responses vary based on baseline sleep patterns, cortisol levels, and underlying contributors to poor sleep. Your clinician will evaluate your progress at regular check-ins and adjust the protocol as needed.
DSIP is generally well tolerated in available research. The most commonly reported effects are transient injection site reactions (mild redness or tenderness that resolves quickly) and, in some patients, unusually vivid dreams — consistent with enhanced slow-wave and REM sleep activity. Unlike sedative sleep aids, DSIP does not cause morning grogginess or cognitive impairment. Long-term human safety data is limited given the absence of large completed clinical trials. Your clinician will review your full health history before prescribing.
Yes. You can pause or cancel at any time through your TruVera patient portal — no phone calls, no cancellation fees. If you have questions about your protocol before canceling, your care team is always available to discuss adjustments.